Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + NK Cells in Advanced HCC
NCT05171309Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous activated and expanded natural killer cells in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate up to 3 years. Status: unknown.
02
Drugs
autologous activated and expanded natural killer cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05171309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171309.